MX2016001691A - Moleculas de union al receptor bag3 para uso como un medicamento. - Google Patents

Moleculas de union al receptor bag3 para uso como un medicamento.

Info

Publication number
MX2016001691A
MX2016001691A MX2016001691A MX2016001691A MX2016001691A MX 2016001691 A MX2016001691 A MX 2016001691A MX 2016001691 A MX2016001691 A MX 2016001691A MX 2016001691 A MX2016001691 A MX 2016001691A MX 2016001691 A MX2016001691 A MX 2016001691A
Authority
MX
Mexico
Prior art keywords
medicament
binding molecules
receptor binding
bag3 receptor
bag3
Prior art date
Application number
MX2016001691A
Other languages
English (en)
Inventor
Caterina Turco Maria
Original Assignee
Biouniversa Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa Srl filed Critical Biouniversa Srl
Publication of MX2016001691A publication Critical patent/MX2016001691A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

La presente invención se refiere al uso de moléculas de unión al receptor BAG3 como un medicamento, particularmente para el uso en el tratamiento de enfermedades de naturaleza inmune, inflamatoria, cardiovascular, neoplásica y/o degenerativa.
MX2016001691A 2013-08-07 2014-07-23 Moleculas de union al receptor bag3 para uso como un medicamento. MX2016001691A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001351A ITMI20131351A1 (it) 2013-08-07 2013-08-07 Molecole leganti il recettore di bag3 per uso terapeutico.
PCT/IB2014/063352 WO2015019230A1 (en) 2013-08-07 2014-07-23 Bag3 receptor binding molecules for use as a medicament

Publications (1)

Publication Number Publication Date
MX2016001691A true MX2016001691A (es) 2016-11-30

Family

ID=49354779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001691A MX2016001691A (es) 2013-08-07 2014-07-23 Moleculas de union al receptor bag3 para uso como un medicamento.

Country Status (13)

Country Link
US (1) US9963514B2 (es)
EP (1) EP3030320B1 (es)
JP (1) JP6511445B2 (es)
KR (1) KR20160037951A (es)
AU (1) AU2014304208B2 (es)
BR (1) BR112016002619A2 (es)
CA (1) CA2920586C (es)
ES (1) ES2731257T3 (es)
IL (1) IL243857A0 (es)
IT (1) ITMI20131351A1 (es)
MX (1) MX2016001691A (es)
RU (1) RU2016107874A (es)
WO (1) WO2015019230A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019017297A (ja) * 2017-07-17 2019-02-07 杭州優瑪達生物科技有限公司Ｈａｎｇｚｈｏｕ ＵＭｏｔｏｒ Ｂｉｏｔｅｃｈ Ｃｏ．， ＬＴＤ． 天然由来および／または自己集合技術によって得られる生体膜、生体膜性質を有する閉合構造または細胞内区画およびその作製方法と応用
EP3658582A1 (en) * 2017-07-28 2020-06-03 Intrepida Bio, Inc. Anti-bag3 antibodies as therapeutic reagent in cardiovascular diseases
SG11202108140SA (en) 2019-02-12 2021-08-30 Medpacto Inc Anti-bag2 antibody and methods of treating cancer
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2004016643A2 (en) * 2002-08-16 2004-02-26 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2009036149A2 (en) * 2007-09-15 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods for treatment of degenerative disease associated with apoptosis
IT1397083B1 (it) 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
ITMI20130403A1 (it) 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico

Also Published As

Publication number Publication date
JP2016527301A (ja) 2016-09-08
KR20160037951A (ko) 2016-04-06
AU2014304208A1 (en) 2016-02-25
EP3030320A1 (en) 2016-06-15
EP3030320B1 (en) 2019-03-20
US20160168255A1 (en) 2016-06-16
US9963514B2 (en) 2018-05-08
RU2016107874A3 (es) 2018-06-15
RU2016107874A (ru) 2017-09-14
CA2920586C (en) 2023-09-12
ITMI20131351A1 (it) 2015-02-08
CA2920586A1 (en) 2015-02-12
IL243857A0 (en) 2016-04-21
ES2731257T3 (es) 2019-11-14
AU2014304208B2 (en) 2020-02-20
JP6511445B2 (ja) 2019-05-15
WO2015019230A1 (en) 2015-02-12
BR112016002619A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
NZ738525A (en) Cot modulators and methods of use thereof
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2016012371A (es) Anticuerpos multiespecificos.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
PH12016500094A1 (en) Autotaxin inhibitors
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
AU355322S (en) Chair
NZ738538A (en) 6-amino-quinoline-3-carbonitrils as cot modulators
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
MX2017006899A (es) Sintesis de polioles polimericos en polioles insaturados, polioles polimericos y su uso.
MX2016010229A (es) Conjugados del factor vii.
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases
MX2015006616A (es) Doble direccion.
NZ733664A (en) Antibodies that bind human c6 and uses thereof